Clinical trial
Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's…
NCT00003499 · Burzynski Research Institute, Other · Completed
Key facts
| NCT number | NCT00003499 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma |
| Official title | Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma Low Grade |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Low-Grade Lymphoma |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 31 |
| Start date | Mar 6, 1996 |
| Primary completion | Sep 13, 2003 |
| Completion | Sep 13, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 24, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: